erlotinib hydrochloride has been researched along with osu 03012 in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (osu 03012) | Trials (osu 03012) | Recent Studies (post-2010) (osu 03012) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 85 | 0 | 55 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | osu 03012 (IC50) |
|---|---|---|---|
| 3-phosphoinositide-dependent protein kinase 1 | Homo sapiens (human) | 5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, GD; Chen, CS; Hung, JH; Kashida, Y; Kulp, SK; Sargeant, AM; Wang, D; Wang, YC; Yamaguchi, M; Yang, CC | 1 |
1 other study(ies) available for erlotinib hydrochloride and osu 03012
| Article | Year |
|---|---|
Targeting endoplasmic reticulum stress and Akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors.
Topics: Actins; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Endoplasmic Reticulum; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazoles; Quinazolines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides | 2008 |